Side-by-side · Research reference
DSIPvsKisspeptin-10
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED8/36 cited
BPhase 2HUMAN-REVIEWED10/41 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
Kisspeptin-10
Neuropeptide · GPR54 Agonist
Phase 1/2Clinical stage
IV / SQ · Investigational
01Mechanism of Action
Parameter
DSIP
Kisspeptin-10
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026Collado-Sole 2026
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026Rønnekleiv 2026
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026
Feedback intact?
—
Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026Rønnekleiv 2026
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
Kisspeptin-10
Frequency
Once daily, pre-sleep
—
Lower / starter dose
50 mcg pre-sleep
—
Duration
8–12 weeks per cycle
—
Reconstitution
Bacteriostatic water
—
Timing
30–60 min pre-sleep
—
Half-life
Short plasma; CNS effects last hours
Short (minutes)
Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.
Clinical trial dose
—
Phase 1/2 investigational
Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).
Route
—
IV or SQ administration
IV preferred in controlled trials for precise pulsatile delivery.
04Side Effects & Safety
Parameter
DSIP
Kisspeptin-10
Injection site reaction
Mild irritation
Erythema, mild discomfort (SQ route)
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
—
Pregnancy / OB
Avoid
—
Ovarian hyperstimulation
—
Theoretical risk with supraphysiological dosing in fertility protocols
Headache
—
Mild, reported in early-phase trials
Nausea
—
Transient GI symptoms with IV bolus
Hot flashes
—
Vasomotor symptoms from LH surge
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
Kisspeptin-10
- ·Active pregnancy
- ·Hormone-sensitive malignancy (breast, ovarian, endometrial)
Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
Kisspeptin-10
- ·Polycystic ovary syndrome (PCOS) without monitoring
- ·Uncontrolled thyroid dysfunction
05Administration Protocol
Parameter
DSIP
Kisspeptin-10
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.
2. Injection site
SQ — abdomen. Rotate sites.
IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.
3. Timing
30–60 min pre-sleep.
Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.
5. Needle
29–31G insulin syringe.
Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.